Abstract
Anti-TNF-alpha therapy is an established treatment modality for inflammatory bowel disease (IBD). Yet up to 30% of patients do not respond to anti-TNF-alpha therapy (primary non-responders), and almost 50% of responders lose clinical efficacy over time (secondary non-responders). Furthermore, numerous safety concerns are associated with the long-term use of anti-TNF-alpha agents. Anti-TNF-alpha therapy safety concerns and the increased incidence of non-responders have driven the need to develop innovative strategies to treat IBD.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
